Emerging Monogenic Complex Hyperkinetic Disorders

Purpose of Review Hyperkinetic movement disorders can manifest alone or as part of complex phenotypes. In the era of next-generation sequencing (NGS), the list of monogenic complex movement disorders is rapidly growing. This review will explore the main features of these newly identified conditions. Recent Findings Mutations in ADCY5 and PDE10A have been identified as important causes of childhood-onset dyskinesias and KMT2B mutations as one of the most frequent causes of complex dystonia in children. The delineation of the phenotypic spectrum associated with mutations in ATP1A3, FOXG1, GNAO1, GRIN1, FRRS1L, and TBC1D24 is revealing an expanding genetic overlap between epileptic encephalopathies, developmental delay/intellectual disability, and hyperkinetic movement disorders,. Summary Thanks to NGS, the etiology of several complex hyperkinetic movement disorders has been elucidated. Importantly, NGS is changing the way clinicians diagnose these complex conditions. Shared molecular pathways, involved in early stages of brain development and normal synaptic transmission, underlie basal ganglia dysfunction, epilepsy, and other neurodevelopmental disorders.


Introduction
Hyperkinetic movement disorders are a heterogeneous group of neurological disorders defined by an excess of involuntary movement production.
Based on the clinical phenomenology, hyperkinetic movement disorders are classified in different clinical entities, including among others dystonia, chorea, and myoclonus. Dystonia is characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, and patterned movements and/or postures. Chorea features continuous and brief involuntary movements, typically flowing from one body part to another in an unpredictable fashion in terms of timing, speed, and direction. Myoclonus defines shock-like involuntary jerks caused by rapid muscle contractions [1].
The etiology of these disorders is often genetically determined, especially in pediatric cases, and mutations in a rapidly growing number of genes have been causally linked to hyperkinetic movement disorders.
Traditionally, a detailed characterization of the predominant movement disorder observed on examination would lay the bases for subsequent investigations, including targeted genetic analysis of mutations in genes that are known to be associated with a specific movement disorder.
However, there are several pitfalls that can make establishing a precise diagnosis on clinical grounds a true challenge. First, multiple hyperkinetic movement disorders are frequently observed together in the same patient with a considerable degree of overlap, which makes defining the predominant type of movement disorder very difficult. Second, the clinical presentation of hyperkinetic movement disorders is often complex and highly variable, which may lead different neurologists to label differently the same movement disorder. Finally, additional neurological features (including intellectual disability (ID), epilepsy, spasticity, ataxia, and structural abnormalities of the brain) are often observed, in variable combinations, especially in cases with pediatric onset.
Hence, it is not surprising how the diagnostic work-up for complex hyperkinetic movement disorders may easily turn into long and painful diagnostic odysseys for patients and their families.
Importantly, the advent of next-generation sequencing (NGS) is rapidly changing the way clinicians diagnose and identify these conditions. Diagnostic approaches based on NGS technologies (i.e., targeted gene sequencing panels or whole-exome sequencing) are progressively becoming a first-line asset in the diagnostic pipeline for these complex disorders, partially bypassing the difficulties of the clinical assessment.
To increase awareness of these individually rare conditions, in this review, we will summarize the main clinical and genetic features of the genetically determined complex hyperkinetic movement disorders identified in the last 5 years (summarized in Table 1).

ADCY5-Related Disorders
The first pathogenic dominant mutation in ADCY5 was identified in a large kindred of German descent initially described in 2001 by Fernandez et al. [2•, 3]. Affected subjects showed an early-onset hyperkinetic movement disorder initially named familial dyskinesia with facial myokimia (FDFM). Subsequently, mutations in this gene were found in patients with childhood-onset chorea and dystonia, as well as in patients with a non-progressive condition resembling benign hereditary chorea (BHC) who tested negative for NKX2-1 mutations [4, 5•]. So far, 70 genetically confirmed cases belonging to 45 different families have been reported [2-4, 5•, 6••, 7-14, 15•, 16]. Since the first description, the phenotype associated to ADCY5 mutations has largely broadened and consequently, the original term FDFM has been replaced by a more comprehensive definition (ADCY5-related dyskinesias). Patients present virtually in all cases with axial hypotonia and delayed motor and/or language milestones during infancy, associated with early-onset chorea with a generalized distribution, classically involving also the facial muscles and the perioral region [5•, 15•]. Dystonic posturing of the limbs and myoclonic jerks can be prominent, mimicking a myoclonus-dystonia-like phenotype but without the classical upper body distribution observed in SGCE mutation carriers [15•, 17]. Episodic exacerbations of movement disorder lasting up to hours have been described in most ADCY5-positive cases, being frequently not only related to sleep but also triggered by febrile illnesses and other various stressors [18]. Such episodes can precede the onset of the chronic movement disorder that eventually dominate patients' clinical picture [15•]. Pyramidal signs in the lower limbs and dysarthria are common clinical findings; in single kindred, dilated cardiomyopathy was reported to cosegregate with ADCY5 mutations in affected individuals, but this finding has never been observed in other families [3]. Both dominant families and sporadic cases due to de novo mutations have been published, with a recurrent missense mutation (p.Arg418Trp) reported in the majority the affected cases. Two additional mutations at amino acidic residue 418 (p.Arg418Gln and p.Arg418Gly) have been subsequently reported, thus indicating that arginine 418 is a mutational hot spot with a relevant pathogenetic role [6••, 8]. The severity of the movement disorder and the consequent degree of functional disability are variable in affected subjects. The available evidence suggests that the p.Arg418Trp mutation is responsible for a more severe clinical picture, whereas the p.Ala726Thr mutation is associated with a milder phenotype [6••, 15•]. Besides genotype-phenotype correlation, somatic mosaicism detected in some mildly affected patients further explains the clinical heterogeneity of ADCY5 mutated subjects [5•, 6••].
In terms of therapy, anticholinergics, benzodiazepines (clonazepam), tetrabenazine, baclofen, neuroleptics, and anticonvulsants alone or in combination have been administered to reduce dyskinesias, with variable response; acetazolamide, a carbonic anhydrase inhibitor, has been successfully used in two patients [2•]. Deep brain stimulation (DBS) of bilateral globus pallidus interna (GPi) has been performed in four patients, with moderate improvement of chorea [9,11].
From a disease mechanism point of view, ADCY5 encodes adenyl cyclase 5 (AC5), an enzyme most abundantly expressed in striatal neurons that converts adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Importantly, dopamine and adenosine modulation of striatal medium spiny neurons (MSNs) is largely mediated through cAMP signaling, as AC5 activity is promoted by the stimulation of the G protein-coupled dopamine receptors type 1 and adenosine receptors 2A [19]. De novo/AD Infancy to fifth decade Abrupt onset of neurological signs (dystonia, muscular weakness, ataxia) Initial hemisomatic distribution Identifiable triggering factors MD, movement disorders; GPCR, guanine nucleotide-binding protein-coupled receptors; NMDAR, glutamatergic N-methyl-D-aspartate receptors; ID, intellectual disability; AHC, alternating hemiplegia of childhood; RDP, rapid-onset dystonia parkinsonism; CAPOS, cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss; DBS, deep brain stimulation

PDE10A-Related Disorders
Both dominant and recessive mutations in this gene have been recently reported in patients with childhood-onset chorea with a generalized distribution and also involving the facial muscles. Two recurrent dominant mutations (p.Phe300Leu and p.Phe334Leu) have been found so far in five unrelated patients worldwide, arising de novo in all but one subject, whose family showed a dominant pattern of inheritance with complete penetrance [20••, 21, 22]. Recessive homozygous mutations (p.Tyr107Cys and p.Ala116Pro) have been detected in eight patients from two consanguineous pedigrees [23••]. Clinically, carriers of dominant mutations display a homogeneous phenotype characterized by early onset (5-15 years) chorea, normal development and cognition, and characteristic symmetrical T2-hyperintense bilateral striatal lesions on brain MRI. Disease course seems to be non-progressive although diurnal fluctuations in childhood and a progressive spreading of chorea during life with increased severity in the elderly have been reported [20••, 21]. Also, levodopa-responsive parkinsonism with abnormal DAT-scan has been described in an adult positive patient [20••]. However, more evidence is needed to establish whether this is truly part of the PDE10A-realted phenotype in the elderly or a chance association. Patients carrying biallelic PDE10A mutations show a more severe phenotype, with markedly delayed motor and language milestones, axial hypotonia, an earlier age at onset of chorea (within 6 months of age), severe dysarthria, and mild ID in some cases. In a single affected subject, childhood-onset epilepsy was also reported. Despite a more severe neurological involvement, the MRI of these cases is normal, without striatal abnormalities observed in cases with dominant mutations [23••].
PDE10A encodes phosphodiesterase 10A, which regulates the degradation of cAMP and cGMP in MSNs of the corpus striatum, where it is highly and selectively expressed. Both recessive and dominant mutations in PDE10A have been shown to lead to a loss of enzymatic function or reduced striatal protein levels [20 Interestingly, preliminary evidence suggests that pathogenic mutations in ADCY5 may act through a gain of function mechanism [4], overall supporting the hypothesis that abnormally increased levels of intracellular cAMP in striatal neurons may represent a key mechanism in the pathogenesis of chorea.

KMT2B-Related Disorders
KMT2B, also known as MLL4, encodes a ubiquitously expressed histone lysine methyltransferase involved in methylation of histone H3 at lysine 4 (H3K4). This gene, located on the chromosomal region 19q13.12, belongs to the SET/ MLL family of proteins, which are essential for activating specific sets of genes during normal development [24]. Consistently, loss-of-function mutations in other MLLencoding genes have been reported in a number of human developmental disorders, such as Kabuki syndrome [25]. Mutations in KMT2B, including interstitial microdeletions detected by microarray at 19q13. 11-19q13.12 28]. KMT2B-related dystonia has been defined "complex" in that additional neurological and systemic features have been recognized in some of the mutation carriers, including psychomotor and language delay, minor dysmorphic traits and a characteristic facial appearance (bulbous nasal tips and elongated face), mild-to-moderate ID, short stature, skin abnormalities, and psychiatric disturbances [26••]. In some patients, the complexity of the clinical phenotype could be partially related to the extension of microdeletions on chromosome 19 leading to haploinsufficiency of a variable number of genes contiguous to KMT2B. Notably, a marked improvement of dystonia with sustained clinical benefit on long-term follow-up has been reported following bilateral GPi DBS, whereas no oral medication is reported to be particularly effective in alleviating motor manifestations [26••, 27••, 28].
Meyer et al. reported a detection rate of KMT2B mutations in up to 38% of patients with early-onset progressive dystonia, suggesting that the contribution of this recently discovered gene to the pathogenesis of childhood-onset dystonia is far higher than most other dystonia-related genes [26••].

ATP1A3-Related Disorders
ATP1A3 gene encodes the α3 isoform of the catalytic subunit of the Na + /K + pump, which is an adenosine triphosphatase (ATPase) cation transporter playing a crucial role in maintaining electrochemical gradients for Na + and K + across the plasma membrane of different cellular types [29]. Mutations affecting the α3 subunit, which is selectively expressed in neurons, were initially linked to three distinct neurological phenotypes, including rapid-onset dystonia parkinsonism (RDP), alternating hemiplegia of childhood (AHC), and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss (CAPOS) syndrome [30][31][32][33]. Other presentations that do not fall within these neurological entities, as well as intermediate and overlapping phenotypes, have emerged in recent years, providing evidence that these conditions are different manifestations of a wide phenotypic spectrum rather than allelic disorders [34•, 35].
Mutations in ATP1A3 arise de novo in most cases of AHC, whereas autosomal dominant transmission has been documented in RDP and CAPOS syndrome cases; moreover, germline mosaicism has been recently reported in two families with recurrence of AHC in offspring of unaffected parents [35,36].
In AHC, symptoms begin before 18 months, and developmental delay is the rule. Clinical manifestations consist of paroxysmal episodes of unilateral hemiplegia or quadriplegia, dystonia, or oculomotor abnormalities (such as monocular nystagmus) which disappear upon sleeping, sometimes only transiently. Episodes last from minutes to several days and can occur with a variable frequency, up to multiple times a day. About half of cases develop epilepsy [37].
In RDP, patients present with abrupt onset of asymmetric dystonia with generally minor features of parkinsonism, with a clear rostro-caudal spreading (face > arm > leg) and prominent bulbar involvement. Symptoms evolve over a few minutes to 30 days, with subsequent stabilization within 1 month; disease course is often biphasic, with a sudden second worsening of symptoms during life. Age at onset ranges from infancy to the fifth decade [38].
In AHC and RDP, clinical manifestations are typically triggered by environmental, physical, or emotional stressors (excitement, strong emotions, physical exertion, febrile illness, excessive environmental stimuli-sounds, light, etc.). The recognition of provocative factors triggering paroxysmal neurological symptoms with an initial hemisomatic distribution represents the most pathognomonic feature to diagnose ATP1A3-related disorders and must be carefully investigated in the patients' clinical history [35].
From a genetic point of view, mutations are distributed over almost all ATP1A3 coding sequence, but RPD phenotypes are mainly associated with mutations in exons 8, 14, and 17, whereas the majority of mutations in patients with AHC are located in exons 17 and 18 [34•]. Available evidence supports a genotype-phenotype correlation with mutations causing classic AHC affecting trans-membrane and functional protein domains; two recurrent missense mutations (p.Asp801Asn and p.Glu815Lys) have been detected in 50% of AHC cases reported. Moreover, only four missense variants have been detected so far in AHC-RDP intermediate phenotypes, and a single recurrent missense mutation (p.Glu818Lys) has been identified in all CAPOS cases [34•, 35].
No specific drugs targeting the altered ionic transport across the Na + /K + pump are available, and symptomatic treatment of acute attacks mostly with benzodiazepines and other sleep inducers is the most frequent therapeutic approach in AHC. Flunarizine is widely used as a prophylactic agent; in a series of 30 AHC patients, it was effective to reduce frequency and duration of attacks in 50% of cases, but no controlled trials are available [42•]. Topiramate is also used with the same aim based on anecdotal reports. In RDP, treatment of dystonia and parkinsonism does not benefit from dopaminergic drugs, and GPi DBS has proven ineffective in a very limited number of cases and also in the authors' experience [43].

GPR88-Related Disorders
Alkufri et al. recently individuated a recessive homozygous truncating mutation (p.Cys291*) in GPR88 in three affected children from a consanguineous Palestinian family [44•]. Patients (all females) presented with developmental delay in infancy, markedly delayed speech and learning disability followed, around 9 years of age, by chorea initially affecting the facial muscles and subsequently spreading to involve upper limbs (mainly distally), trunk, and tights. Chorea showed a slow but constant progression over a period of months, without further worsening few years after the onset. Severe mental retardation (IQ 40 in one subject) and a scarcely progressive movement disorder therefore seem to be key phenotypic features of this disorder. So far, no additional cases following the original publication have been reported.
The GPR88 gene encodes a G protein-coupled receptor (GPCR) abundantly expressed both in D1R-and D2Rexpressing MSNs, which are, respectively, part of the direct and indirect pathway [45].
MSNs from GPR88 knock-out mice show increased glutamatergic excitability and reduced GABAergic inhibition, which results in enhanced firing rates in vivo, producing a murine phenotype characterized by hyperactivity, impaired motor coordination, and motor learning [46].

Hyperkinetic Movement Disorders in Epileptic-Dyskinetic Encephalopathies
Early onset encephalopathies are a heterogeneous group of diseases characterized by severe dysfunction of cognitive, sensory, and motor development. The etiology of these disorders is variable and includes acquired causes such as prematurity, congenital infections and hypoxic insult at birth, as well as various genetic defects that disrupt brain function, or its normal structure and development. Early-onset, often drug-resistant seizures are a recurrent feature of several encephalopathies. In recent years, the co-occurrence of hyperkinetic movement disorders (chorea, dystonia, ballismus, complex stereotypies) in early-onset epileptic encephalopathies (EOEE) has been increasingly recognized and detailed, to the point that movement disorders are now considered a core feature of several EOEE. These conditions, currently referred to as "epileptic-dyskinetic encephalopathies" (MIM: 308350), are clinically and genetically heterogeneous and encompass various degrees of ID and severe, often intractable epilepsy in association with hyperkinetic movement disorders. Altered functioning of glutamatergic NMDA and AMPA receptors as well as impaired neurotransmission and synaptic plasticity in early neurodevelopmental stages seem to be relevant pathogenetic mechanisms that can give rise to a wide spectrum of variably associated neurological symptoms including movement disorders, ID, and epilepsy.

FOXG1-Related Disorders
FOXG1 (Forkhead Box G1) gene, a transcription repressor, plays a crucial role in fetal telencephalon development and is an important component of the transcription regulatory network that controls proliferation, differentiation, neurogenesis, and neurite outgrowth in the cerebral cortex, hippocampus, and basal ganglia [47,48]. Mutations in FOXG1 cause a distinct developmental encephalopathy manifesting in infancy or early childhood with severe developmental delay, acquired microcephaly, profound ID, epilepsy, and absent language (so called "congenital Rett syndrome"; OMIM 613454) [49]. Corpus callosum hypoplasia or aplasia, delayed myelination, simplified gyration, and fronto-temporal abnormalities are frequent radiological findings. Beyond these core features, the phenotypic spectrum of FOXG1 mutations has recently expanded to include early-onset, complex hyperkinetic movement disorders featuring various combinations of chorea, dystonia, dyskinesia, myoclonus, and hand stereotypies that are virtually observed in all positive patients and become evident since the first years of life [50]. In a series of 28 patients, chorea was the most frequent movement disorder (88%), followed by orolingual/facial dyskinesia (80%) and dystonia (76%); movement disorder course was progressive in about half of cases, with remarkable severity and disability [51••]. In a recent review of 83 novel and published cases, dyskinesias and hand stereotypies were both reported in 90% of patients whose clinical data were available. A definite genotypephenotype correlation has not been established, although truncating FOXG1 mutations in the N-terminal and the forkhead domains (except conserved site 1) are associated with more severe phenotypes, whereas missense variants in the forkhead conserved site 1 seem to be responsible for milder phenotypes, with independent ambulation, spoken language, normal head growth, and ability to use hands [51••, 52].
Several drugs have shown little or no benefit in alleviating FOXG1 movement disorders, although levodopa, tetrabenazine, and pimozide were partially beneficial in single cases [50, 51••].
Hyperkinetic movements similar to those observed in FOXG1 have also been reported in carriers of CDKL5 mutations, transmitted as an X-linked trait. Mutations in this gene are associated with variant Rett syndrome characterized by onset of refractory seizures within the first weeks of life inconstantly associated with movement disorders [53].
The differential diagnosis of FOXG1-related phenotypes includes other epileptic-dyskinetic encephalopathies such as ARX-related encephalopathy (characterized by infantile spasms, neonatal-onset progressive dystonia with recurrent status dystonicus, and severe mental retardation) and three conditions caused by de novo mutations in genes essential for neurotransmitter release through synaptic vesicle fusion [54][55][56]. These include mutations in STXBP1 (featuring infantile-onset epilepsy with good prognosis, tremor, and frequent paroxysmal non-epileptic movement disorders), SYT1 (associated with severe developmental delay and an early onset, paroxysmal dyskinetic movement disorder worsening at night), and UNC13A (linked to developmental and speech delay, ID, dyskinesias, and intention tremor, with febrile seizures as a minor feature) [57][58][59].

GNAO1-Related Disorders
GNAO1 encodes a subclass (Gαo) of the Gα subunit of heterotrimeric guanine nucleotide-binding proteins which is highly expressed in the brain, where it is involved in the regulation of neuronal excitability and neurotransmission. De novo mutations in GNAO1 were initially associated with Ohtahara syndrome, a severe type of early epileptic encephalopathy characterized by neonatal tonic spasms, severe motor developmental delay, and ID with a suppression-burst pattern on EEG [60,61]. GNAO1-related encephalopathy has been further characterized following the individuation of additional mutation carriers, and hyperkinetic movements have emerged as an important core feature, being universally present in affected subjects. Patients present in most cases a combination of generalized chorea associated with dystonia, which manifest within the first months or years of life, with a median age at onset around 2 years [62••]. Facial and oro-lingual dyskinesia and complex stereotypies have been reported as well. Movement disorders display a chronic course with characteristic episodic exacerbations triggered by high temperature, infections, emotions, and purposeful movements lasting from minutes to days and even months and often being accompanied by dysautonomic manifestations (sweating, tachycardia, hypertemia, diaphoresis) and thus being potentially lifethreatening [63]. Exacerbations have a variable frequency and can present in clusters up to several times a day. While developmental delay and severe ID are features consistently associated with GNAO1 mutations, epilepsy is variably present and often follows the onset of movement disorders of months or years [64•].
So far, 45 genetically proven patients have been reported, harboring 25 different mutations (23 missense, one splice site, one deletion) [62••, 64•, 65-69]. Glutamine at position 246 (Glu246) and arginine at position 209 (Arg209), both highly conserved amino acids, are GNAO1 mutational hotspots, and missense mutations involving these residues have been reported in about half (21/45, 46.7%) of published cases. A genotype-phenotype correlation has recently been suggested in functional in vitro studies, with GNAO1 loss-of-function mutations associated with epileptic encephalopathy and gain-of-function or normally functioning alleles leading to phenotypes dominated by movement disorders [70••].
Tetrabenazine and neuroleptics seem to be the most effective drugs to treat movement disorders in GNAO1 mutation carriers; in severe drug-resistant cases, bilateral GPi DBS has significantly improved the frequency and severity of exacerbations as well as patients' motor performances, although the baseline movement disorder seems to remain rather constant even after DBS implant [66,71,72].

GRIN1-Related Disorders
GRIN1 encodes the GluN1 subunit of the glutamatergic Nmethyl-D aspartate receptors (NMDAR), which are heteromeric protein complexes acting as ion channels upon ligand activation [73]. GluN1 subunits have a key role in the plasticity of synapses, which underlies memory and learning [74]. De novo heterozygous variants of GRIN1 were first linked to non-syndromic ID with or without epilepsy [75]. So far, 34 positive patients from 30 different families have been reported [76, 77•, 78-80]. The vast majority of mutations are heterozygous variants arising de novo, but recessive biallelic mutations have also been described in seven patients from three different consanguineous kindred [77•, 78]. GRIN1 positive patients present in almost all cases with severe developmental delay, cognitive dysfunction, and profound ID since early infancy. About 70% of cases develop early-onset, polymorphic seizures with non-specific EEG patterns that are drug-resistant in about one third of cases. Hyperkinetic movement disorders (mainly a combination of chorea and dystonia) have been observed in about 60% of patients, and complex stereotypies as well as oculogyric crises resembling those of monoamine neurotransmitter disorders are frequently reported, being an important diagnostic clue [77•]. Additional features include spastic tetraparesis, cortical blindness, non-specific sleep disturbances, subtle dysmorphism, and microcephaly. All de novo GRIN1 mutations cluster within or in close proximity of the transmembrane domains of GluN1, a highly-conserved region; in vitro studies demonstrated that variants in this position lead to a dominant negative effect, whereas one of the reported homozygous variants (c.649C>T; p.Arg217Trp) causes impaired activation of the NMDA receptor [77•]. Moreover, a GRIN1 truncating variant (c.1666C>T; p.Gln556*), resulting in GRIN1 haploinsufficiency, seems to be tolerated in a heterozygous state, not producing a neurological phenotype; however, when in homozygosity, it has proven responsible for a fatal neonatal epileptic encephalopathy [77•].

FRRS1L-Related Disorders
The FRRS1L gene encodes a component of the outer core of AMPA receptor accessory proteins. Glutamatergic AMPA receptors represent the most common receptor subtype in the brain, mediating fast glutamatergic excitatory postsynaptic potentials. Using a combination of homozygosity mapping and WES, Madeo et al. recently identified four different homozygous mutations in FRRS1L in eight patients from four different pedigrees, two of which were consanguineous [81••]. Six additional patients from a large consanguineous Arab kindred have subsequently been reported [82]. Affected subjects present around 20 months of age with psychomotor regression after a phase of normal development, followed by the onset of progressive choreoatethosis and ballismus and severe encephalopathic epilepsy. Differently from GNAO1 positive patients, the severity of movement disorders seems to decrease over disease course, giving way to an akinetic-rigid phenotype in late adolescence, and no episodic exacerbations have been reported [81••].

TBC1D24-Related Disorders
TBC1D24 is involved in synaptic vesicles trafficking and is expressed in multiple human tissues, with the highest expression in the brain [83]. Recessive homozygous or compound heterozygous mutations in TBC1D24 have been linked to several human diseases, ranging from nonsyndromic deafness to a wide spectrum of epilepsies, whereas dominant mutations have been linked to a type of nonsyndromic hearing loss. The most common epilepsy phenotype consists of early-onset myoclonic epilepsy, myoclonic seizures (often occurring in clusters), and drug-resistance. About 50 epileptic patients carrying TBC1D24 have been reported worldwide, with heterogeneous presentations and prognosis [84•]. In a recent review of new and published cases, 39/48 (81%) presented mild to profound intellectual disability, which therefore appears to be a frequently encountered clinical feature. Moreover, dystonia (sometimes with a hemisomatic distribution) was reported in 7/48 (14.5%) of patients as well as in a recently published case with a complex phenotype including epilepsy, infantile-onset parkinsonism, cerebellar signs, and psychosis [85]. Cortical myoclonus affecting lower limbs with gait impairment has also been reported [86].

Conclusions
In the last 5 years, the list of genes associated with dystonia, chorea, myoclonus, and mixed movement disorders has dramatically expanded and so has the phenotype associated with mutations in individual genes.
Our systematic review of the recent literature shows that an unexpected variety of molecular causes underlie complex hyperkinetic disorders. Several genes, though individually very are, can be responsible for the same phenotypes and, on the other hand, mutations in a given gene can be associated with several phenotypes, which are often part of spectrum and not discrete entities (as exemplified by ATP1A3-related disorders). With some exceptions (e.g., ADCY5-, KMT2B-, ATP1A3-related movement disorders), the number of reported patients affected by these novel genetic entities is still rather limited. Therefore, our knowledge about the clinical features and natural history of these disorders will only grow once larger case series will become available.
Importantly, NGS is challenging the traditional-and often problematic-approach to patients with hyperkinetic movement disorders, based on the recognition of "core clinical features." The increasing availability of NGS in clinical practice will hopefully help to formulate definite diagnoses in a larger number of patients affected by complex movement disorders, allowing clinicians to provide families with appropriate genetic counseling and disease-specific therapies.

Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
Open Access This article is distributed under the terms of the Creative Comm ons Attribution 4.0 International License (http:// creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.